Repare Therapeutics Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDRepare Therapeutics Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 110% provides fundamental context to the price action. Investors should exercise caution due to high volatility (58% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.59 | +2.37% | ABOVE |
| 50 SMA | $2.37 | +12.03% | ABOVE |
| 100 SMA | $2.07 | +27.74% | ABOVE |
| 150 SMA | $1.90 | +39.66% | ABOVE |
| 200 SMA | $1.76 | +50.35% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RPTX in an uptrend right now?
RPTX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RPTX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RPTX overbought or oversold?
RPTX's RSI (14) is 74. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RPTX outperforming the market?
RPTX has a Relative Strength (RS) Rating of 89 out of 99. Yes, RPTX is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is RPTX in its 52-week range?
RPTX is trading at $2.65, which is 100% of its 52-week high ($2.66) and 99% above its 52-week low ($1.37).
How volatile is RPTX?
RPTX has a Beta of 0.31 and 52-week volatility of 58%. It's less volatile than the S&P 500 - generally more stable.